Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Funahashi on Enhanced Activity With Lenvatinib/Everolimus Combo in RCC

Yasuhiro Funahashi, MD
Published: Thursday, May 26, 2016

Yasuhiro Funahashi, MD, senior director, Eisai, discusses a study exploring the enhanced antitumor activity with the combination of lenvatinib (Lenvima) and everolimus (Afinitor) in patients with renal cell carcinoma (RCC).

Using human xenograft models, researchers found that the combination in this group of patients caused tumor regression and had no body weight loss. An immunohistochemistry analysis revealed a decrease of microvessel density in the lenvatinib and combination arms, as well as a decrease in the proportion of proliferative cells.

Results also showed that the treatment of lenvatinib in combination with everolimus caused significant antitumor effect in the xenograft models. These preclinical data provide a mechanism to support the significant clinical benefit observed in RCC with the combination of lenvatinib and everolimus.
Yasuhiro Funahashi, MD, senior director, Eisai, discusses a study exploring the enhanced antitumor activity with the combination of lenvatinib (Lenvima) and everolimus (Afinitor) in patients with renal cell carcinoma (RCC).

Using human xenograft models, researchers found that the combination in this group of patients caused tumor regression and had no body weight loss. An immunohistochemistry analysis revealed a decrease of microvessel density in the lenvatinib and combination arms, as well as a decrease in the proportion of proliferative cells.

Results also showed that the treatment of lenvatinib in combination with everolimus caused significant antitumor effect in the xenograft models. These preclinical data provide a mechanism to support the significant clinical benefit observed in RCC with the combination of lenvatinib and everolimus.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x